Anzeige
Mehr »
Login
Samstag, 02.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
Technischer Ausbruch: Diese Kupferaktie ist in den letzten 52 Wochen um 300 % gestiegen! Der Durchbruch läuft!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3D7CA | ISIN: US03836J2015 | Ticker-Symbol:
NASDAQ
01.11.24
14:30 Uhr
3,950 US-Dollar
+0,040
+1,02 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
APREA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
APREA THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur APREA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
23.10.Aprea Therapeutics, Inc. - 8-K, Current Report1
14.10.Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit3
09.10.APRE stock touches 52-week low at $2.22 amid market challenges1
09.10.Aprea Therapeutics, Inc. - 8-K, Current Report1
09.10.Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development1
09.09.Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference1
04.09.APRE stock touches 52-week low at $3.17 amid market challenges1
28.08.Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference1
21.08.Aprea Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
12.08.Aprea Therapeutics GAAP EPS of -$0.58, revenue of $561.57M1
12.08.Aprea Therapeutics Inc reports results for the quarter ended in June - Earnings Summary1
12.08.APRE stock touches 52-week low at $3.22 amid market challenges1
12.08.Aprea Therapeutics, Inc. - 8-K, Current Report1
12.08.Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update107Enrollment commenced in the ACESOT-1051 Phase 1 trial evaluating APR-1051 - no myelosuppression observed in the first of eight planned cohorts at sub-therapeutic dose $28.7 million in cash and cash...
► Artikel lesen
12.08.Aprea Therapeutics, Inc. - 10-Q, Quarterly Report1
21.06.Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 20241
17.06.Aprea Therapeutics, Inc. - 8-K, Current Report1
17.06.Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051132APR-1051 is a highly selective and potentially best-in-class oral WEE1 inhibitor Phase 1 ACESOT-1051 clinical trial is evaluating APR-1051 as monotherapy treatment in patients with significant unmet...
► Artikel lesen
28.05.Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial2
14.05.Aprea Therapeutics GAAP EPS of -$0.671
Seite:  Weiter >>
32 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1